ReviewJournal of neurology2014
Recent advances in Parkinson’s disease genetics.
Review in Journal of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 75 citations in OpenAlex.
- Expanding Horizons in Parkinson's Disease: Towards Integrated Care and Comprehensive Research.Journal of clinical medicine · 2025Article
- Cell-Based Covalent-Capture Deubiquitinase Assay for Inhibitor Discovery.ACS pharmacology & translational science · 2024Article
- Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine.Frontiers in aging neuroscience · 2024Review
- GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy.Journal of movement disorders · 2023Article
- Abnormalities in Copper Status Associated with an Elevated Risk of Parkinson's Phenotype Development.Antioxidants (Basel, Switzerland) · 2023Review
- Neural progenitor cells derived from fibroblasts induced by small molecule compounds under hypoxia for treatment of Parkinson's disease in rats.Neural regeneration research · 2023Article
- mTORC1-Dependent Protein and Parkinson's Disease: A Mendelian Randomization Study.Brain sciences · 2023Article
- Narrative Review Concerning the Clinical Spectrum of Ophthalmological Impairments in Parkinson's Disease.Neurology international · 2023Review
- Review
- Inhibition of miR-421 Preserves Mitochondrial Function and Protects against Parkinson's Disease Pathogenesis via Pink1/Parkin-Dependent Mitophagy.Disease markers · 2022Article
- Supramolecular organizing centers at the interface of inflammation and neurodegeneration.Frontiers in immunology · 2022Review
- Clustered regularly interspaced short palindromic repeats as an advanced treatment for Parkinson's disease.Brain and behavior · 2021Review
- Assessing the relationship between monoallelic PRKN mutations and Parkinson's risk.Human molecular genetics · 2021Article
- Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models.Frontiers in neurology · 2021Review
- Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset.Movement disorders : official journal of the Movement Disorder Society · 2020Article
- Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer's Disease.Molecular neurobiology · 2020Review
- CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.Cellular and molecular neurobiology · 2020Review
- Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.Signal transduction and targeted therapy · 2020Review
- Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.Brain : a journal of neurology · 2019Article
- Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The last 5 years have seen rapid progress in Parkinson’s disease (PD) genetics, with the publication of a series of large-scale genome wide association studies for PD, and evaluation of the roles of the LRRK2 and GBA genes in the aetiology of PD. We are beginning to develop a coherent picture of the interplay of Mendelian and non-Mendelian factors in PD. Pathways involved in mitochondrial quality control (mitophagy), lysosomal function and immune function are emerging as important in the pathogenesis of PD. These pathways represent a target for therapeutic intervention and a way in which the heterogeneity of disease cause, as well as disease mechanism, can be established. In the future, there is likely to be an individualised basis for the treatment of PD, linked to the identification of specific genetic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.